{"denoms":[{"counts":[{"groupId":"BG000","value":"71"}],"units":"Participants"}],"groups":[{"description":"All patients received IV fludarabine 30 mg/m2/day on days -7 through -3; busulfan 6.4 mg/kg by continuous infusion over 48 hours on days -6 through -5 and tacrolimus from day -1. Throughout the study duration, 8 different GVHD regimens were investigated. In addition to tacrolimus, patients received combinations of 3 agents: methotrexate (5 mg/m2 D1, 3, 6), rabbit antithymocyte globulin (ATG, 3 mg/kg to- 6 mg/kg) or alemtuzumab (Campath, 30 mg to- 90 mg).","id":"BG000","title":"All Trial Participants"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"28","upperLimit":"69","value":"58"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"40"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"60"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"37"}]}],"title":"HLA-matched related donor (MRD)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"34"}]}],"title":"MUD or HLA-mismatched grafts"}],"description":"Human leukocyte antigen (HLA) typing is used to match a recipient with a donor for bone marrow or cord blood transplant. Donor types are either HLA-matched related donor (MRD) or matched unrelated donor (MUD) or HLA-mismatched grafts.","paramType":"COUNT_OF_PARTICIPANTS","title":"Donor Types","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"8","value":"3"}]}]}],"description":"The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) was developed to identify relevant comorbidities in the allogeneic stem cell transplantation population and to enable risk assessment before allogeneic transplant. Comorbidities are given a a weighted score of 1 to 3 if present. The total score can range from 0 to 29, with higher numbers indicating more/worse comorbidities. The HCT-CI scores were further collapsed into 3 risk groups: 0 (low risk), 1 to 2 (intermediate risk), and 3 or more (high risk).","dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Comorbidity Index (CI)","unitOfMeasure":"units on a scale"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"}]}],"title":"Low"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"}]}],"title":"Intermediate"},{"categories":[{"measurements":[{"groupId":"BG000","value":"19"}]}],"title":"High"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}],"title":"Very High"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"}]}],"title":"Undetermined"}],"description":"The DRI uses a combination of a ternary breakdown for disease type and a binary breakdown for remission status to assign patients to 1 of 4 risk categories that differ very significantly (statistically and clinically) with respect to overall survival (OS) and Progression free survival (PFS).","paramType":"COUNT_OF_PARTICIPANTS","title":"Disease Risk Index (DRI)","unitOfMeasure":"Participants"}]}